Evaluate the predictive performance of amikacin plasma concentration using the Bayesian approach in critically ill patients at Bach Mai Hospital
Cơ quan, tổ chức của tác giả
DOI:
https://doi.org/10.59882/1859-364X/216Từ khóa:
Bayesian approach, popPK, predictive performance, amikacin, critically ill patientsTóm tắt
Purpose: This study aimed to externally validate the population pharmacokinetic (popPK) model of amikacin and assess the applicability of Bayesian forecasting approach in individualizing amikacin dosing for critically ill patients.
Materials and Methods: Retrospective data from 121 ICU patients with 231 blood amikacin concentrations were used to evaluate the predictive performance of the model published by A.H. Nguyen which was developed previously from patients in the same department. The model was evaluated based on a priori and a posteriori approach using relative bias (rBias), relative root mean squared error (rRMSE), and Visual Predictive Checks. For Bayesian forecasting, the study investigated the ability to predict peak concentrations by using solely a middle level in dosing interval. The rBias and rRMSE and the clinical agreement evaluation based on a threshold of 45 mg/L was applied for this purpose. The forecast performance between Bayesian estimation and first-order pharmacokinetic calculation was compared based on trough concentrations, with Bias and RMSE indices.
Results: The A.H. Nguyen model was appropriate for both a priori and a posteriori prediction, with rBias values of 18.40% and 2.42%, respectively. The Bayesian forecasting method demonstrated good predictive performance when comparing forecasted peak concentrations to observations, with rBias of 6.81% and rRMSE of approximately 30%. An excellent agreement (over 85%) between observed- and forecast-peak concentrations was achieved. No difference was found in forecasting trough concentration by Bayesian estimation using one-level or two-level. However, the trough level estimated by the Bayesian methods resulted in a positive bias of 1.25 mg/L in comparison with first-order PK calculation.
Conclusions: The A.H. Nguyen model could be applicable in a model-based TDM for Vietnamese ICU patients. Bayesian forecasting using only middle concentration might be sufficient for the dose individualization of amikacin for both efficacy and safety monitoring.
Tài liệu tham khảo
Safdar N, Handelsman J, Maki DG: Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004, 4(8):519-527.
Pea F, Viale P, Furlanut M: Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44(10):1009-1034.
Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F et al: Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med 2020, 46(6):1127-1153.
Barclay ML, Kirkpatrick CM, Begg EJ: Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999, 36(2):89-98.
Begg EJ, Barclay ML, Duffull SB: A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995, 39(6):605-609.
Burton ME, Brater DC, Chen PS, Day RB, Huber PJ, Vasko MR: A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 1985, 37(3):349-357.
Ryan AC, Carland JE, McLeay RC, Lau C, Marriott DJE, Day RO, Stocker SL: Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing. Br J Clin Pharmacol 2021, 87(3):1422-1431.
Sheiner LB, Beal S, Rosenberg B, Marathe VV: Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979, 26(3):294-305.
Nguyễn Hoàng Anh: Phân tích dược động học quần thể và mô phỏng PK/PD của amikacin ở bệnh nhân nặng điều trị tại Khoa Hồi sức tích cực - Bệnh viện Bạch Mai. Luận văn Thạc sĩ Dược học, Trường Đại học Dược Hà Nội 2022.
Broeker A, Nardecchia M, Klinker KP, Derendorf H, Day RO, Marriott DJ, Carland JE, Stocker SL, Wicha SG: Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. Clin Microbiol Infect 2019, 25(10):1286 e1281-1286 e1287.
Cunio CB, Uster DW, Carland JE, Buscher H, Liu Z, Brett J, Stefani M, Jones GRD, Day RO, Wicha SG et al: Towards precision dosing of vancomycin in critically ill patients: an evaluation of the predictive performance of pharmacometric models in ICU patients. Clin Microbiol Infect 2020.
Queensland Health: Aminoglycoside Dosing in Adults. 2018.
Hughes JH, Keizer RJ: A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. CPT Pharmacometrics Syst Pharmacol 2021, 10(10):1150-1160.
Duong A, Simard C, Wang YL, Williamson D, Marsot A: Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling? Antibiotics (Basel) 2021, 10(5).
